Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Nephrology
•
Glomerulonephritis
Do you take any special treatment considerations for elderly patients diagnosed with collapsing FSGS?
Related Questions
When would you recommend starting immunosuppression in patients diagnosed with Henoch-Schönlein purpura and IgA nephropathy who have proteinuria < 1 gram per day and eGFR > 60 mL/min who are already on ACEi and SGLT2i?
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
What drives you to choose voclospsorin over tacrolimus given the substantially higher cost?
What are some indications that might lead you to pursue a kidney biopsy in a patient with presumed diabetic kidney disease?
What is your approach to the management of secondary membranous nephropathy with nephrotic range proteinuria?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
Do you ever combine voclosporin and belimumab in the treatment of lupus nephritis?
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
Do you prefer a mycophenolate or tacrolimus based glucocorticoid-sparing regimen for patients with minimal change disease?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
